Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex Incorporated (NYSE: TFX) reported its Q4 2022 financial results, with revenues of $758.0 million, a slight decline of 0.5% year-over-year, but a 3.7% rise on a constant currency basis. GAAP diluted EPS decreased to $1.65 from $2.69 in Q4 2021. For full year 2022, revenues were $2,791.0 million, down 0.7%, with a GAAP diluted EPS of $7.67, compared to $10.23 in 2021. Looking ahead, Teleflex expects revenue growth of 4.25% to 5.75% for 2023, and GAAP EPS guidance of $8.26 to $8.86. The company emphasizes its commitment to durable growth amidst challenges.
Teleflex Incorporated (NYSE: TFX) announced significant advancements in interventional cardiology with the FDA 510(k) clearance of the Triumph™ Catheter and the first clinical use of the GuideLiner® Coast™ Catheter. The Triumph™ Catheter features six wire exit ports designed for better navigation in complex anatomy. Developed with Dr. Bill Nicholson, it aims to improve catheter navigation. The GuideLiner® Coast™ Catheter adds hydrophilic options to the existing portfolio. Both products will be showcased at the CTO Plus Conference on February 23-24 in New York, with full market release expected later in 2023.
Teleflex Incorporated (NYSE: TFX) will have its Chairman, President, and CEO, Liam Kelly, speaking at the 44th Annual Raymond James Institutional Investors Conference on March 7, 2023, at 1:40 p.m. (ET). The conference will take place at the JW Marriott Orlando Grande Lakes, Orlando, FL.
A live audio webcast and accompanying presentation slides will be available on the investor section of Teleflex's website for those unable to attend in person.
Teleflex specializes in innovative medical technologies that improve healthcare quality, offering solutions across various medical fields.
Teleflex Incorporated (NYSE: TFX) will hold a conference call on February 23, 2023, at 8:00 AM ET to discuss its fourth-quarter financial results and provide an operational update. Interested participants can pre-register for the call through a provided link or access it via a live audio webcast on the company’s website. A replay of the call will be available later that day. Teleflex is a leading global provider of medical technologies, focusing on innovative solutions across various healthcare sectors including vascular access, anesthesia, and emergency medicine. For more details, visit their official website.
Teleflex (NYSE: TFX) announced a new agreement with Premier®, Inc. for its Titan SGS® powered stapling device, designed for sleeve gastrectomy procedures. This collaboration enables Premier members to access competitive pricing on the Titan SGS®, which is uniquely indicated for gastric pouch creation. The device has proven to cut staple time in half and facilitates consistent gastric anatomy, boasting a 23cm staple line. Over 6,000 procedures have utilized the Titan SGS® since its 2021 launch. Teleflex's partnership with Premier is expected to enhance the distribution of this advanced surgical technology nationwide.
Teleflex (NYSE: TFX) has launched a national advertising campaign to promote the UroLift® System, an innovative, minimally invasive treatment for benign prostatic hyperplasia (BPH). This humorous campaign emphasizes the importance of health screenings for men and aims to encourage visits to urologists. BPH, which affects many aging men, can cause disruptive urinary symptoms. The UroLift® System has treated over 400,000 men globally, offering a solution without severe side effects like erectile dysfunction. The 5-year durability data shows a 2-3% surgical retreatment rate annually.
Teleflex, a global provider of medical technologies, announced that Liam Kelly, its Chairman, President, and CEO, will speak at the 41st Annual J.P. Morgan Healthcare Conference. The event is set for January 10, 2023, at 3:00 p.m. PT in San Francisco, California. A live audio webcast and presentation slides will be accessible on the Teleflex investor website. Teleflex focuses on innovative solutions in various medical fields, including vascular access and emergency medicine. More information can be found at teleflex.com.
Liam Kelly, Chairman, President and CEO of Teleflex, will present at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 1:30 p.m. (ET). A live audio webcast of the presentation can be accessed via the investor section of the Teleflex website. Teleflex specializes in medical technologies that enhance health and quality of life, with innovative solutions in vascular access, interventional cardiology, anesthesia, and more. For additional details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a worldwide recall of specific lots of its Gibeck® Iso-Gard® Filters due to potential risks including splitting or detaching during use, which could compromise patient air supply. The recall, which affects products manufactured between December 17, 2019, and March 26, 2022, was expanded after 38 complaints were reported, including 4 injuries related to patient desaturation, but no deaths or long-term injuries. The FDA classified the recall as Class I, indicating serious health risks associated with the affected filters.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
